140
Participants
Start Date
December 19, 2016
Primary Completion Date
February 21, 2019
Study Completion Date
April 21, 2021
entinostat
An orally available histone deacetylases inhibitor (HDACi).
avelumab
A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.
Placebo
A pill containing no active drug ingredient.
Memorial Sloan Kettering Cancer Center, New York
University of Pennsylvania, Philadelphia
Greater Baltimore Medical Center, Baltimore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore
University of Virginia, Charlottesville
Florida Cancer Specialist East Region (SCRI Affiliate), West Palm Beach
H. Lee Moffitt Cancer Center and Research, Tampa
Sarah Cannon Research Institute, Nashville
University of Chicago, Chicago
HCA Midwest Health (SCRI Affiliate), Kansas City
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Lead Sponsor
Collaborators (1)
Merck KGaA, Darmstadt, Germany
INDUSTRY
Pfizer
INDUSTRY
Syndax Pharmaceuticals
INDUSTRY